Literature DB >> 12383609

Bacterial eradication in the treatment of otitis media.

Ron Dagan1, Eugene Leibovitz.   

Abstract

Drugs differ in their ability to eradicate various pathogens from the middle-ear cavity during acute otitis media (AOM), and these differences clearly affect clinical outcome. Outcome is derived from differences in the association between concentrations of the drugs at the site of infection and the antimicrobial effect (termed pharmacodynamics). These differences are even more marked in the present era of antimicrobial resistance. However, since AOM is a self-limiting disease in most cases, difference in clinical outcome is more difficult to ascertain than that of bacteriological outcome, which is measured within 3-5 days. A favourable clinical outcome regardless of the bacteriological effect of the drug can result in false optimism when less-effective antibiotic drugs are used. Inappropriate study design and manipulation of clinical results add to this confusion. In this review we attempt to highlight the evidence regarding bacteriological response to antibiotics in AOM and to draw attention to potential flaws that may mislead clinicians.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383609     DOI: 10.1016/s1473-3099(02)00394-8

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  15 in total

Review 1.  A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Authors:  A Dalhoff; P G Ambrose; J W Mouton
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

2.  Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996-1997 to 2006-2007).

Authors:  Emilio Pérez-Trallero; Jose E Martín-Herrero; Ana Mazón; Celia García-Delafuente; Purificación Robles; Victor Iriarte; Rafael Dal-Ré; Juan García-de-Lomas
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

Review 3.  Appropriate treatment of acute otitis media in the era of antibiotic resistance.

Authors:  Ron Dagan
Journal:  Paediatr Drugs       Date:  2010-06-29       Impact factor: 3.022

4.  Parental acceptability of the watchful waiting approach in pediatric acute otitis media.

Authors:  Arnon Broides; Olga Bereza; Noga Lavi-Givon; Yariv Fruchtman; Eli Gazala; Eugene Leibovitz
Journal:  World J Clin Pediatr       Date:  2016-05-08

5.  A randomized, double-blind, placebo-controlled noninferiority trial of amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years of age.

Authors:  Nicole Le Saux; Isabelle Gaboury; Marian Baird; Terry P Klassen; Johnna MacCormick; Colline Blanchard; Carrol Pitters; Margaret Sampson; David Moher
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

Review 6.  Acute otitis media in children aged less than 2 years: drug treatment issues.

Authors:  Eugene Leibovitz
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 7.  Short-course therapy for community-acquired pneumonia in paediatric patients.

Authors:  Shamim Qazi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Interspecies bacterial communication as a target for therapy in otitis media.

Authors:  Chelsie E Armbruster; W Edward Swords
Journal:  Expert Rev Anti Infect Ther       Date:  2010-10       Impact factor: 5.091

9.  Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.

Authors:  Melinda M Pettigrew; Brian T Tsuji; Janneane F Gent; Yong Kong; Patricia N Holden; Sanjay Sethi; Timothy F Murphy
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

Review 10.  Antimicrobial resistance in Haemophilus influenzae.

Authors:  Stephen Tristram; Michael R Jacobs; Peter C Appelbaum
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.